Hanmi Pharm. Co., Ltd. is a Korea-based company primarily engaged in the manufacture of pharmaceuticals. Founded in 1973, it has shown remarkable growth and emerged as a leading player among Korean pharmaceutical companies. Hanmi is recognised as a global leader in the production of high-quality active pharmaceutical ingredients (APIs) for a range of therapeutic categories, including cephalosporins, cardiovascular drugs, anti-diabetics, gastrointestinal treatments, and central nervous system (CNS) medications. The company's facilities have been inspected and approved by regulatory authorities including the UK MHRA, German BSG, Australian TGA, and US FDA. Hanmi has successfully developed and marketed new combination drugs and a series of innovative medicinal drugs (IMDs) through its patented processes, as well as developed its unique LAPSCOVERY technology.

Services include:
- Manufacture of prescription drugs
- Production of active pharmaceutical ingredients (APIs)
- Development of new combination drugs
- Creation of innovative medicinal drugs (IMDs)
- Quality assurance and compliance with international standards

Hanmi Pharm. Co., Ltd continues to lead in the pharmaceutical industry with its commitment to quality and innovation. For more information, please visit hanmi.co.kr.